Oligonucleotide Synthesis Market By Product & Service (Synthesizer, Custom Oligonucleotide Synthesis, Probes, Premiers, Linkers & Adaptors and Reagents & Consumables), By End-User (Pharmaceutical & Biotechnology Companies, Academic Research Institutes, Diagnostic Laboratories and Others), By Application (Research, Therapeutics and Diagnostics), and By Region- Trends, Analysis and Forecast till 2030

Oligonucleotide Synthesis Market accounted for USD 5.17 Billion in 2020 and is estimated to be USD 12.09 Billion by 2030 and is anticipated to register a CAGR of 9.0%.

Enzymatic chemistry and genetic engineering produce oligonucleotides, which are little fragments of nucleic acids. Oligonucleotides are mostly used in research laboratories for diagnostic, educational, and industrial purposes, as well as medicinal purposes. Oligonucleotide synthesis can be done professionally to serve a large number of customers, or it can be done independently using DNA synthesizers. Improvements in oligonucleotide synthesis, amplification, and computerization have completely altered biological research in recent years. It is also possible to make adjustments and obtain the required cycle quickly and easily online. The cost per base pair, error rates, durations, and throughput, among other factors, all affect the cost of these vital services.

Impact of Covid-19 pandemic on market

New generations of oligonucleotide medications, including mRNA and DNA vaccines, are currently being developed in response to the rising number of cases of coronavirus illness (COVID-19) and the need for a viable cure. Apart from that, the rising prevalence of cancer and other chronic illnesses has increased the demand for novel diagnostics, impacting the need for oligonucleotide synthesis to aid in the development of effective medicines and diagnostic tools. The industry is also being boosted by the growing elderly population and need for tailored treatments.

Decrease in cost of DNA sequencing drives the market

Over the last few years, advances in genomics research have resulted in a significant reduction in the cost of genome sequencing. NGS technology has drastically decreased the cost and enhanced the speed of DNA sequencing. The cost of sequencing a human genome has reduced significantly, according to statistics from the National Human Genome Research Institute (NHGRI), from around $5 million in 2008 to around $1,000 in 2017. Sequencing is increasingly being employed in genomics research to comprehend the various nature of reproductive medicine, oncology, and infectious illnesses, in addition to assembling genomes and investigating the genetic basis of human disorders.

Increasing government support and investment

Governments in a number of nations have made major investments in programmes connected to synthetic biology and genomics in recent years. These government investments have aided the development of new technology significantly. Oligonucleotides are an important aspect of these technologies, and increased investment and development in these domains will fuel oligonucleotide market growth. For instance, The Department of Biotechnology (DBT) launched the "Genome India Project" in January 2020. (GIP). The goal of the initiative is to collect 10,000 genetic samples from Indian residents in order to create a reference genome. Precision health, rare genetic disorders, the mutation spectrum of genetic and complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research are some of the project major areas.

Oligonucleotide Synthesis Market report segments the market on the basis of product and service, application, end-user and region.

On the basis of Product and Service, the Oligonucleotide Synthesis Market is segmented into Synthesizer, Custom Oligonucleotide Synthesis, Probes, Premiers, Linkers & Adaptors and Reagents & Consumables. On the basis of Application, the target market is segmented into Research, Therapeutics and Diagnostics. Based on End-User, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic Research Institutes, Diagnostic Laboratories and Others.

Regional Insights:

Oligonucleotide Synthesis Market accounted for US$ 5.17 billion in 2020 and is estimated to be US$ 12.09 billion by 2030 and is anticipated to register a CAGR of 9.0%. On region the Oligonucleotide Synthesis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The oligonucleotide synthesis market is expected to be dominated by North America in 2020, followed by Europe. During the projection period, however, demand from the Asia-Pacific region is predicted to expand at the quickest CAGR. Some of the primary reasons supporting the growth of the oligonucleotides market in the APAC region include increasing availability of synthesized oligonucleotides, strong presence of pharma and biotech businesses, expanding research outsourcing to CROs, and increased R&D funding and activities. For many stakeholders in the oligonucleotide synthesis business, developed countries such as the United States and European nations have been major marketplaces.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the Oligonucleotide Synthesis Market report based on product & service, application, end-user and Region.

Oligonucleotide Synthesis Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • U.S.
  • Canada

The key players operating in the Oligonucleotide Synthesis Market includes Integrated DNA Technologies, Inc. (U.S.) (Part of Danaher Corporation), Merck KGaA (Germany), Eurofins Scientific SE (Luxembourg), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), GE Healthcare (U.S.), GeneDesign, Inc. (Japan) (Part of Ajinomoto Co.,Inc.), Kaneka Eurogentec (Belgium) (Part of Kaneka Corporation), LGC Biosearch Technologies (U.S.), Bio-synthesis Inc. (U.S.), TriLink BioTechnologies, LLC (U.S.) (Part of Maravai LifeSciences), and ATDBio Ltd. (U.K.) among others.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is a scientific instrumentation, reagents and consumables, and software Services Company based in the United States. Oligo (dT)18 Primer from Thermo Scientific is a single-stranded 18-mer oligonucleotide with 5' and 3' hydroxyl ends. The primer comes as a 20X concentrated aqueous solution that is ready to use. The most cost-effective and quickest option to order oligonucleotides from us is through Value Oligos. Simply enter your sequence and then proceed to the checkout page. Value Oligos come in 25 nmol and 50 nmol sizes, with several purifying techniques.

• Microsynth AG (Switzerland) provided key reagents such as primer-probe sets to PCR testing labs in April 2020 to help molecular diagnostic companies develop and validate accurate, cutting-edge detection methods, as well as to provide comprehensive genomics expertise to research labs studying coronaviruses. The main contribution involves, among other things, the supply of SARS-CoV-2 detection RT-qPCR primer-probe sets and the synthesis of primers for NGS-based SARS-CoV-2 high-throughput diagnostic.
• Bio-Synthesis Inc. (US) released ready-to-use cocktail mixes for COVID-19 study in June 2020, including the SARS-CoV-2 N1 Oligo Mix, the SARS-CoV-2 N2 Oligo Mix, and the Human RNase P (RP) Oligo Mix.

• Integrated DNA Technologies, Inc.
• Merck KGaA
• Eurofins Scientific SE
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
• GE Healthcare
• GeneDesign, Inc.
• Kaneka Eurogentec
• LGC Biosearch Technologies
• Bio-synthesis Inc.